AAPL 174.545 3.0981% MSFT 400.8 -1.3585% GOOG 168.575 -2.9449% GOOGL 166.78 -3.0067% AMZN 180.55 0.5178% NVDA 872.0 -0.6098% META 432.1 -2.5243% TSLA 193.965 15.2564% TSM 137.52 -0.564% LLY 735.26 0.2386% V 272.48 -0.7431% AVGO 1336.05 -0.5967% JPM 193.42 -0.0362% UNH 490.57 -0.965% NVO 127.045 0.1537% WMT 60.075 -0.1413% LVMUY 167.187 -1.2422% XOM 119.54 1.3394% LVMHF 834.7 -1.2014% MA 457.31 -1.1051%
Last update at 2024-04-29T17:22:00Z
| Breakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
| Income before tax | -7.08900M | -4.50732M | -6.45598M | -2.33166M | -2.36882M |
| Minority interest | - | - | - | - | - |
| Net income | -7.14000M | -4.53104M | -6.46904M | -2.33905M | -2.39306M |
| Selling general administrative | 6.08M | 5.70M | 4.61M | 2.27M | 2.03M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.45M | 2.98M | 0.50M | 1.78M | 1.29M |
| Reconciled depreciation | 0.35M | 0.59M | 0.38M | 0.40M | 0.16M |
| Ebit | -7.22300M | -4.53396M | -6.52248M | -2.40285M | -2.41279M |
| Ebitda | -6.87200M | -3.91250M | -6.07976M | -1.93302M | -2.20587M |
| Depreciation and amortization | 0.35M | 0.62M | 0.44M | 0.47M | 0.21M |
| Non operating income net other | - | - | 0.07M | - | 0.04M |
| Operating income | -7.22300M | -4.53396M | -6.52248M | -2.40285M | -2.41279M |
| Other operating expenses | 12.56M | 23.41M | 13.72M | 9.10M | 7.61M |
| Interest expense | - | 0.03M | 0.00037M | 0.00001M | 0.00005M |
| Tax provision | 0.05M | 0.02M | 0.01M | 0.00739M | 0.02M |
| Interest income | 0.13M | 0.03M | 0.07M | 0.07M | 0.04M |
| Net interest income | 0.13M | 0.03M | 0.07M | 0.07M | 0.04M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.05M | 0.02M | 0.01M | 0.00739M | 0.02M |
| Total revenue | 5.34M | 18.87M | 7.20M | 6.69M | 5.20M |
| Total operating expenses | 7.67M | 7.51M | 7.02M | 4.18M | 3.70M |
| Cost of revenue | 4.89M | 15.89M | 6.70M | 4.91M | 3.91M |
| Total other income expense net | 0.00100M | 0.03M | 0.07M | 0.07M | 0.04M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -7.14000M | -4.53104M | -6.46904M | -2.33905M | -2.39306M |
| Net income applicable to common shares | -7.14000M | -4.53104M | -6.46904M | -2.33905M | -2.39306M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
| Total assets | 14.45M | 11.37M | 11.82M | 17.26M | 5.25M |
| Intangible assets | 0.17M | 0.17M | 0.29M | 0.17M | 0.11M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.30M | 0.00045M | 0.00026M | 1.51M | 0.20M |
| Total liab | 2.73M | 3.05M | 2.59M | 3.05M | 1.26M |
| Total stockholder equity | 11.72M | 8.32M | 9.23M | 14.21M | 3.98M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.24M | 0.88M | 0.54M | 0.28M | 0.26M |
| Common stock | 1.35M | 1.03M | 0.98M | 0.94M | 0.77M |
| Capital stock | 1.35M | 1.03M | 0.98M | 0.96M | 0.77M |
| Retained earnings | -42.21700M | -35.07738M | -28.39477M | -21.92573M | -19.58668M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.08M | 0.00036M | 0.26M | 0.17M | 0.13M |
| Cash | 9.72M | 5.92M | 4.20M | 8.64M | 0.69M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.95M | 2.01M | 1.30M | 1.48M | 1.26M |
| Current deferred revenue | 0.06M | 0.05M | - | - | - |
| Net debt | -8.63700M | -4.53740M | -2.57980M | -6.85954M | -0.68678M |
| Short term debt | 0.30M | 0.34M | 0.33M | 0.21M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.08M | 1.38M | 1.62M | 1.78M | - |
| Other stockholder equity | 52.70M | 42.45M | 36.69M | 35.21M | 22.83M |
| Property plant equipment | 1.25M | 1.52M | 1.86M | 1.99M | 0.35M |
| Total current assets | 12.80M | 9.43M | 9.23M | 14.77M | 4.49M |
| Long term investments | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Net tangible assets | 11.56M | 8.16M | 8.93M | 14.02M | 3.87M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.72M | 0.77M | 1.46M | 1.77M | 1.45M |
| Long term debt | - | - | - | - | - |
| Inventory | 2.06M | 2.42M | 3.21M | 2.85M | 2.15M |
| Accounts payable | 0.34M | 0.74M | 0.43M | 0.99M | 1.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.11000M | -0.07394M | -0.04796M | -0.03984M | -0.03653M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.98M | 0.94M | 0.77M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -28.39477M | - | -19.58668M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.08M | 0.10M | 0.26M | 0.17M | 0.13M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.66M | 1.95M | 2.59M | 2.49M | 0.75M |
| Capital lease obligations | 1.08M | 1.38M | 1.62M | 1.78M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
| Investments | -0.07800M | -0.17034M | -0.29558M | -0.11893M | -0.17111M |
| Change to liabilities | -0.08000M | 0.39M | -0.40333M | -0.01288M | 0.36M |
| Total cashflows from investing activities | -0.07800M | -0.17034M | -0.29558M | -0.11893M | -0.17111M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 9.39M | 2.39M | 1.11M | 12.37M | 1.91M |
| Change to operating activities | -0.20100M | 0.28M | 0.91M | -1.49573M | 0.10M |
| Net income | -7.14000M | -4.53104M | -6.46904M | -2.33905M | -2.39306M |
| Change in cash | 3.80M | 1.72M | -4.44172M | 7.95M | -0.51812M |
| Begin period cash flow | 5.92M | 4.20M | 8.64M | 0.69M | 1.20M |
| End period cash flow | 9.72M | 5.92M | 4.20M | 8.64M | 0.69M |
| Total cash from operating activities | -5.47400M | -0.48053M | -5.25175M | -4.29750M | -2.24404M |
| Issuance of capital stock | 10.01M | 2.40M | 1.01M | 12.15M | 1.78M |
| Depreciation | 0.35M | 0.59M | 0.38M | 0.40M | 0.16M |
| Other cashflows from investing activities | - | - | -0.15973M | - | -0.06997M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.53M | 1.56M | -1.90601M | -0.71746M | 0.02M |
| Change to account receivables | -0.29100M | 1.37M | -0.45561M | -0.30909M | -0.67013M |
| Sale purchase of stock | - | - | 1.11M | - | 1.90M |
| Other cashflows from financing activities | -0.62400M | -0.00721M | 0.10M | 2.14M | 0.13M |
| Change to netincome | 1.35M | -0.14314M | 2.69M | 0.18M | 0.18M |
| Capital expenditures | 0.08M | 0.17M | 0.30M | 0.12M | 0.17M |
| Change receivables | - | - | -0.45561M | - | -0.67013M |
| Cash flows other operating | - | - | 1.28M | - | 0.09M |
| Exchange rate changes | - | - | -0.00812M | - | -0.01039M |
| Cash and cash equivalents changes | - | - | -4.44172M | - | -0.51812M |
| Change in working capital | -0.03800M | 2.91M | -1.85299M | -2.53729M | -0.18802M |
| Stock based compensation | 1.19M | 1.26M | 0.38M | 0.20M | 0.15M |
| Other non cash items | 0.17M | -0.71915M | 2.32M | -0.03797M | 0.01M |
| Free cash flow | -5.55200M | -0.65087M | -5.54733M | -4.41643M | -2.41515M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMRA Biomerica Inc |
-0.0838 12.60% | 0.58 | - | - | 4.35 | 2.19 | 3.06 | -2.7471 |
| ABT Abbott Laboratories |
-0.455 0.42% | 107.08 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
3.46 1.03% | 339.07 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
1.28 1.60% | 81.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.58 0.79% | 72.59 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
17571 Von Karman Avenue, Irvine, CA, United States, 92614
| Name | Title | Year Born |
|---|---|---|
| Mr. Zackary S. Irani | Chairman & CEO | 1966 |
| Mr. Allen C. Barbieri | Exec. Vice-Chairman & Corp. Sec. | 1958 |
| Mr. Steven Sloan | CFO & Treasurer | 1970 |
| Ms. Lucy Liu Ph.D. | Director of Manufacturing & Technical Operations | NA |
| Hans Boehringer | Sr. VP of POC R&D | NA |
| Mr. Robert W. Carlson | Chief Commercial Officer | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...